TrialThe Lancet. Oncology2020

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.

Yelena Y Janjigian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.